Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 50.44
BIOL's Cash to Debt is ranked higher than
72% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.21 vs. BIOL: 50.44 )
Ranked among companies with meaningful Cash to Debt only.
BIOL' s 10-Year Cash to Debt Range
Min: 0.08  Med: 3.54 Max: No Debt
Current: 50.44
Equity to Asset 0.61
BIOL's Equity to Asset is ranked higher than
54% of the 179 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.60 vs. BIOL: 0.61 )
Ranked among companies with meaningful Equity to Asset only.
BIOL' s 10-Year Equity to Asset Range
Min: -0.35  Med: 0.42 Max: 0.91
Current: 0.61
-0.35
0.91
F-Score: 2
Z-Score: -1.41
M-Score: -1.53
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -39.86
BIOL's Operating margin (%) is ranked lower than
83% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.56 vs. BIOL: -39.86 )
Ranked among companies with meaningful Operating margin (%) only.
BIOL' s 10-Year Operating margin (%) Range
Min: -357.14  Med: -17.46 Max: 14.2
Current: -39.86
-357.14
14.2
Net-margin (%) -41.25
BIOL's Net-margin (%) is ranked lower than
82% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.77 vs. BIOL: -41.25 )
Ranked among companies with meaningful Net-margin (%) only.
BIOL' s 10-Year Net-margin (%) Range
Min: -686.67  Med: -24.30 Max: 39.05
Current: -41.25
-686.67
39.05
ROE (%) -80.80
BIOL's ROE (%) is ranked lower than
89% of the 180 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.29 vs. BIOL: -80.80 )
Ranked among companies with meaningful ROE (%) only.
BIOL' s 10-Year ROE (%) Range
Min: -6372.65  Med: -73.05 Max: 110.88
Current: -80.8
-6372.65
110.88
ROA (%) -45.27
BIOL's ROA (%) is ranked lower than
88% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.52 vs. BIOL: -45.27 )
Ranked among companies with meaningful ROA (%) only.
BIOL' s 10-Year ROA (%) Range
Min: -282.19  Med: -33.71 Max: 62.83
Current: -45.27
-282.19
62.83
ROC (Joel Greenblatt) (%) -267.50
BIOL's ROC (Joel Greenblatt) (%) is ranked lower than
88% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 11.56 vs. BIOL: -267.50 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
BIOL' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -493.08  Med: -129.35 Max: 231.63
Current: -267.5
-493.08
231.63
Revenue Growth (3Y)(%) -10.80
BIOL's Revenue Growth (3Y)(%) is ranked lower than
82% of the 152 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.00 vs. BIOL: -10.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
BIOL' s 10-Year Revenue Growth (3Y)(%) Range
Min: -27.9  Med: 11.20 Max: 105.4
Current: -10.8
-27.9
105.4
EBITDA Growth (3Y)(%) 56.30
BIOL's EBITDA Growth (3Y)(%) is ranked higher than
95% of the 128 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.90 vs. BIOL: 56.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
BIOL' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -49.5  Med: -3.60 Max: 100
Current: 56.3
-49.5
100
EPS Growth (3Y)(%) 44.20
BIOL's EPS Growth (3Y)(%) is ranked higher than
91% of the 127 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.70 vs. BIOL: 44.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
BIOL' s 10-Year EPS Growth (3Y)(%) Range
Min: -54.3  Med: -3.10 Max: 148.4
Current: 44.2
-54.3
148.4
» BIOL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

BIOL Guru Trades in Q3 2014

Mario Gabelli 91,455 sh (unchged)
George Soros Sold Out
» More
Q4 2014

BIOL Guru Trades in Q4 2014

Mario Gabelli 91,455 sh (unchged)
» More
Q1 2015

BIOL Guru Trades in Q1 2015

Chuck Royce 166,581 sh (New)
Mario Gabelli 91,455 sh (unchged)
» More
Q2 2015

BIOL Guru Trades in Q2 2015

Mario Gabelli 91,455 sh (unchged)
Chuck Royce Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with BIOL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 10.09
BIOL's Forward P/E is ranked higher than
92% of the 75 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 21.41 vs. BIOL: 10.09 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 2.59
BIOL's P/B is ranked higher than
52% of the 176 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.89 vs. BIOL: 2.59 )
Ranked among companies with meaningful P/B only.
BIOL' s 10-Year P/B Range
Min: 0.87  Med: 6.62 Max: 42.47
Current: 2.59
0.87
42.47
P/S 1.50
BIOL's P/S is ranked higher than
69% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.71 vs. BIOL: 1.50 )
Ranked among companies with meaningful P/S only.
BIOL' s 10-Year P/S Range
Min: 0.13  Med: 1.75 Max: 5.44
Current: 1.5
0.13
5.44
Current Ratio 2.52
BIOL's Current Ratio is ranked higher than
52% of the 183 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.42 vs. BIOL: 2.52 )
Ranked among companies with meaningful Current Ratio only.
BIOL' s 10-Year Current Ratio Range
Min: 0.63  Med: 1.49 Max: 8.29
Current: 2.52
0.63
8.29
Quick Ratio 1.76
BIOL's Quick Ratio is ranked higher than
56% of the 183 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.60 vs. BIOL: 1.76 )
Ranked among companies with meaningful Quick Ratio only.
BIOL' s 10-Year Quick Ratio Range
Min: 0.34  Med: 1.08 Max: 7.75
Current: 1.76
0.34
7.75
Days Inventory 147.13
BIOL's Days Inventory is ranked lower than
60% of the 181 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 128.59 vs. BIOL: 147.13 )
Ranked among companies with meaningful Days Inventory only.
BIOL' s 10-Year Days Inventory Range
Min: 68.7  Med: 115.58 Max: 407.12
Current: 147.13
68.7
407.12
Days Sales Outstanding 73.32
BIOL's Days Sales Outstanding is ranked lower than
67% of the 161 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 62.83 vs. BIOL: 73.32 )
Ranked among companies with meaningful Days Sales Outstanding only.
BIOL' s 10-Year Days Sales Outstanding Range
Min: 17.25  Med: 55.06 Max: 223.06
Current: 73.32
17.25
223.06

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 3.21
BIOL's Price/Net Current Asset Value is ranked higher than
77% of the 114 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.94 vs. BIOL: 3.21 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
BIOL' s 10-Year Price/Net Current Asset Value Range
Min: 3.74  Med: 18.40 Max: 233.6
Current: 3.21
3.74
233.6
Price/Tangible Book 2.88
BIOL's Price/Tangible Book is ranked higher than
63% of the 156 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.28 vs. BIOL: 2.88 )
Ranked among companies with meaningful Price/Tangible Book only.
BIOL' s 10-Year Price/Tangible Book Range
Min: 3.42  Med: 14.34 Max: 178.9
Current: 2.88
3.42
178.9
Price/Median PS Value 0.84
BIOL's Price/Median PS Value is ranked higher than
69% of the 167 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.15 vs. BIOL: 0.84 )
Ranked among companies with meaningful Price/Median PS Value only.
BIOL' s 10-Year Price/Median PS Value Range
Min: 0.24  Med: 1.93 Max: 34.63
Current: 0.84
0.24
34.63
Earnings Yield (Greenblatt) (%) -32.83
BIOL's Earnings Yield (Greenblatt) (%) is ranked lower than
94% of the 185 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.90 vs. BIOL: -32.83 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BIOL' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -33.47  Med: 1.50 Max: 2.3
Current: -32.83
-33.47
2.3

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:BTH.Germany,
Biolase Inc was originally formed as Societe Endo Technic, SA ("SET") in 1984 in Marseilles, France. In 1987, SET merged into Pamplona Capital Corp., a public holding company incorporated in Delaware. In 1994, it changed its name to BIOLASE Technology, Inc. and to BIOLASE, Inc. ("BIOLASE") in 2012. The Company is a biomedical company that develops, manufactures, and markets lasers in dentistry and medicine and also markets and distributes dental imaging equipment, including cone beam digital x-rays and CAD/CAM intra-oral scanners, and in-office, chair-side milling machines and three-dimensional ("3-D") printers; products that are focused on technologies that advance the practice of dentistry and medicine. Its proprietary dental laser systems allows dentists, periodontists, endodontists, oral surgeons, and other specialists to perform a dental procedures, including cosmetic, restorative, and complex surgical applications. Its systems are designed to provide performance for many types of dental procedures with less pain and faster recovery times than are generally achieved with drills, scalpels, and other conventional instruments. The Company has clearance from the U.S. Food and Drug Administration (the "FDA") to sell its laser systems in the United States and also have the necessary registration to sell its laser systems in Canada, the European Union, and various other international markets. Its licensed dental imaging equipment and other related products are designed to improve diagnoses, applications, and procedures in dentistry and medicine. It offers two categories of laser system products: WaterLase systems and Diode systems. Its WaterLase system, uses a patented combination of water and laser energy to perform most procedures currently performed using dental drills, scalpels, and other traditional dental instruments for cutting soft and hard tissue. It also offers Diode laser systems to perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. It currently has approximately 180 issued and 120 pending U.S. and international patents, the majority of which are related to WaterLase technology and dental and medical lasers.
» More Articles for BIOL

Headlines

Articles On GuruFocus.com
Viral Cross-Contamination Risks at the Dentist Office Jan 14 2015 
UPDATE - Ebola and Other Viral Cross-Contamination Risks at the Dentist Office Jan 14 2015 

More From Other Websites
BIOLASE, INC Financials Aug 19 2015
10-Q for BIOLASE, Inc. Aug 09 2015
BIOLASE, INC Files SEC form 10-Q, Quarterly Report Aug 07 2015
Biolase reports 2Q loss Aug 05 2015
Biolase reports 2Q loss Aug 05 2015
BIOLASE, INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Aug 05 2015
BIOLASE Reports 2015 Second Quarter Results Aug 05 2015
Q2 2015 BIOLASE Inc Earnings Release - After Market Close Aug 05 2015
Align Technology, Inc. Earnings Analysis: By the Numbers Jul 30 2015
BIOLASE® to Host 2015 Second Quarter Financial Results Conference Call on August 5, 2015 Jul 29 2015
BIOLASE, INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and... Jul 15 2015
BIOLASE Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4) Jul 15 2015
BIOLASE, the global leader in dental lasers, features groundbreaking periodontal protocol as part of... Jun 05 2015
BIOLASE, INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Jun 05 2015
BIOLASE Comments on Recent Decline in Stock Price Jun 05 2015
BIOLASE, INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Jun 02 2015
BIOLASE, INC Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD... May 18 2015
Veteran Dental Executive Harold C. Flynn Jr. to Become President and CEO of BIOLASE May 18 2015
BIOLASE, INC Files SEC form 10-Q, Quarterly Report May 01 2015
Biolase reports 1Q loss Apr 30 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK